REG - Ondine Biomedical - Result of AGM and voting results

Ondine BiomedicalAnnouncement

Thu 18:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nRSZ6453Oa&default-theme=true

RNS Number : 6453O  Ondine Biomedical Inc.  26 June 2025

26 June 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Result of AGM and voting results

Ondine Biomedical (AIM: OBI) announces that all resolutions set out in the
Notice of AGM dated 4 June 2025 were duly passed at its Annual General Meeting
("AGM") held on 26 June 2025.

The voting results of the AGM were as follows:

                             In Favor             Against      Withheld
 Resolution                  Votes        %       Votes  %     Votes      %
 1. Election of Directors    305,312,279  100.00  0      0.00  0          0.00
 Carolyn Cross               305,312,279  100.00  0      0.00  0          0.00
 Nicolas G. Loebel           305,312,279  100.00  0      0.00  0          0.00
 Jean Charest                305,312,279  100.00  0      0.00  0          0.00
 Jean Duvall                 302,712,279  99.05   0      0.00  2,900,000  0.95
 Junaid Bajwa                302,712,279  99.05   0      0.00  2,900,000  0.95
 Margaret Shaw               305,312,279  100.00  0      0.00  0          0.00
 2. Appointment of Auditors  305,312,279  100.00  0      0.00  0          0.00

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEAKKKASXSEFA